Chemical features of melanoma tumor resident TRG CDR3s associated with better survival probabilities
- PMID: 37222076
- DOI: 10.1097/CMR.0000000000000899
Chemical features of melanoma tumor resident TRG CDR3s associated with better survival probabilities
Abstract
We assessed the T-cell receptor gamma (TRG) recombination reads from the cancer genome atlas melanoma tumor exome files and the TRG recombination reads from an independent, melanoma exome file dataset, from the Moffitt Cancer Center. TRG complementarity determining region-3 (CDR3) amino acid (AA) sequences were assessed for chemical complementarity to cancer testis antigens, with such complementarity for FAM133A and CRISP2 associated with better survival probabilities for both datasets. These results, along with related TRG CDR3 AA chemical feature assessments provided in this report, have indicated opportunities for melanoma patient stratifications based on the recovery of TRG recombination reads from both tumor and blood samples, and the results may point towards novel, effective melanoma antigens.
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Similar articles
-
Chemical complementarity between tumor resident, T-cell receptor CDR3s and MAGEA3/6 correlates with increased melanoma survival: Potential relevance to MAGE vaccine auto-reactivity.Mol Immunol. 2022 Oct;150:58-66. doi: 10.1016/j.molimm.2022.08.001. Epub 2022 Aug 17. Mol Immunol. 2022. PMID: 35987136
-
High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer.Mol Immunol. 2021 Jul;135:247-253. doi: 10.1016/j.molimm.2021.02.026. Epub 2021 Apr 29. Mol Immunol. 2021. PMID: 33933816
-
TRB CDR3-cancer testis antigen chemical complementarity scoring for identifying productive immune responses in renal cell carcinoma.Cancer Biomark. 2023;38(1):103-110. doi: 10.3233/CBM-230047. Cancer Biomark. 2023. PMID: 37545223
-
A scoring system for the electrostatic complementarities of T-cell receptors and cancer-mutant amino acids: multi-cancer analyses of associated survival rates.Immunology. 2020 Apr;159(4):373-383. doi: 10.1111/imm.13165. Epub 2020 Jan 21. Immunology. 2020. PMID: 31821535 Free PMC article.
-
Antigen recognition by gammadelta T cells.Immunol Rev. 2007 Feb;215:46-58. doi: 10.1111/j.1600-065X.2006.00470.x. Immunol Rev. 2007. PMID: 17291278 Review.
Cited by
-
Chemical Complementarity of Blood-Sourced, Breast Cancer-Related TCR CDR3s and the CMV UL29 and IE1 Antigens is Associated with Worse Overall Survival.Biochem Genet. 2024 Oct 2. doi: 10.1007/s10528-024-10934-y. Online ahead of print. Biochem Genet. 2024. PMID: 39356353
References
-
- Bassani-Sternberg M, Braunlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S, et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun 2016; 7:13404.
-
- Ralli M, Botticelli A, Visconti IC, Angeletti D, Fiore M, Marchetti P, et al. Immunotherapy in the treatment of metastatic melanoma: current knowledge and future directions. J Immunol Res 2020; 2020:9235638.
-
- Hotz MJ, O’Halloran EA, Hill MV, Hayden K, Zaladonis AG, Deng M, et al. Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma. Melanoma Res 2022; 32:112–119.
-
- Harrer DC, Simon B, Fujii SI, Shimizu K, Uslu U, Schuler G, et al. RNA-transfection of gamma/delta T cells with a chimeric antigen receptor or an alpha/beta T-cell receptor: a safer alternative to genetically engineered alpha/beta T cells for the immunotherapy of melanoma. BMC Cancer 2017; 17:551.
-
- Argentati K, Re F, Serresi S, Tucci MG, Bartozzi B, Bernardini G, et al. Reduced number and impaired function of circulating gamma delta T cells in patients with cutaneous primary melanoma. J Invest Dermatol 2003; 120:829–834.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical